MiNK Therapeutics (NASDAQ:INKT) Upgraded by B. Riley to "Strong-Buy" Rating

B. Riley upgraded shares of MiNK Therapeutics (NASDAQ:INKT - Free Report) to a strong-buy rating in a research report released on Friday,Zacks.com reports.

A number of other equities research analysts have also weighed in on the company. William Blair lowered MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 11th. HC Wainwright lowered MiNK Therapeutics from a "strong-buy" rating to a "neutral" rating and set a $35.00 price target on the stock. in a research note on Tuesday.

MiNK Therapeutics Stock Performance

INKT traded down $2.94 during trading on Friday, reaching $20.31. The company's stock had a trading volume of 677,478 shares, compared to its average volume of 244,710. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $76.00. The company's fifty day moving average price is $10.44 and its 200-day moving average price is $9.18. The company has a market capitalization of $81.04 million, a price-to-earnings ratio of -8.06 and a beta of 0.19.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.09). Equities analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.